References

Diffuse large B-cell lymphoma

10.1056/nejmra2027612 · 2021 · External reference

The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms

10.1038/s41375-022-01620-2 · 2022 · External reference

Large B-cell lymphomas in the 5th edition of the WHO-classification of haematolymphoid neoplasms-updated classification and new concepts

10.3390/cancers15082285 · 2023 · External reference

The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH

10.1182/blood.2019002600 · 2019 · External reference

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2

10.1182/blood.2024025603 · 2024 · External reference

RNAseq analysis for accurate identification of fusion partners in tumor specific translocations detected by standard FISH probes in hematologic malignancies

10.1177/2632010x241230262 · 2024 · External reference

Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential

10.1038/s41375-023-02134-1 · 2024 · External reference

Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium

10.1200/jco.19.00743 · 2019 · External reference

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

10.1182/blood-2015-05-647602 · 2015 · External reference

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology

10.1182/bloodadvances.2018023572 · 2018 · External reference

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements

10.3324/haematol.2018.190157 · 2018 · External reference

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

10.1038/s41408-024-01148-x · 2024 · External reference

Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study

10.1158/1078-0432.ccr-15-2305 · 2016 · External reference

LYmphoid NeXt-Generation Sequencing (LYNX) Panel: a comprehensive capture-based sequencing tool for the analysis of prognostic and predictive markers in lymphoid malignancies

10.1016/j.jmoldx.2021.05.007 · 2021 · External reference

Integrated genomic DNA/RNA profiling vs fluorescence in situ hybridization in the detection of MYC and BCL2 (and BCL6) rearrangements in La-ge B-cell lymphomas: updates amid the new WHO classification of lymphoid neoplasms

10.1093/ajcp/aqad006 · 2023 · External reference

Comparison between integrated genomic DNA/RNA profiling and fluorescence in situ hybridization in the detection of MYC, BCL-2, and BCL-6 gene rearrangements in large B-cell lymphomas

10.1093/ajcp/aqz172 · 2020 · External reference

Detection of gene fusions and rearrangements in formalin-fixed, paraffin-embedded solid tumor specimens using high-throughput chromosome conformation capture

10.1016/j.jmoldx.2025.01.007 · 2025 · External reference

Large B-cell lymphoma with mystery rearrangement: applying Hi-C to the detection of clinically relevant structural abnormalities

10.1111/bjh.19611 · 2024 · External reference

Evaluation of Hi-C sequencing for detection of gene fusions in hematologic and solid tumor pediatric cancer samples

10.3390/cancers16172936 · 2024 · External reference

Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies

10.1016/j.xgen.2026.101166 · 2025 · External reference

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

10.1038/modpathol.2013.214 · 2014 · External reference

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

10.3324/haematol.2012.066209 · 2013 · External reference

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

10.1182/blood-2012-10-460063 · 2013 · External reference

Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL

10.1158/2326-6066.cir-18-0439 · 2019 · External reference

Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL

10.1158/1078-0432.ccr-23-1554 · 2023 · External reference

Arima SV Pipeline for Mapping, SV Detection and QC

2025 · External reference

HiCUP: pipeline for mapping and processing Hi-C data

10.12688/f1000research.7334.1 · 2015 · External reference

Integrative detection and analysis of structural variation in cancer genomes

10.1038/s41588-018-0195-8 · 2018 · External reference

Juicer provides a one-click system for analyzing loop-resolution Hi-C experiments

10.1016/j.cels.2016.07.002 · 2016 · External reference

Juicebox provides a visualization system for Hi-C contact maps with unlimited zoom

10.1016/j.cels.2015.07.012 · 2016 · External reference

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

10.1038/leu.2012.83 · 2012 · External reference

Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

10.1002/cncr.28664 · 2014 · External reference

Genetics of diffuse large B-cell lymphoma

10.1182/blood-2017-11-764332 · 2018 · External reference

Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

10.1186/s40425-019-0730-x · 2019 · External reference

Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma

10.1158/1078-0432.ccr-15-2296 · 2016 · External reference

The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee

10.1182/blood.2022015851 · 2022 · External reference

A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas

10.1038/s41375-022-01764-1 · 2023 · External reference

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma

10.1182/blood-2016-05-715094 · 2016 · External reference

B-cell receptor silencing reveals the origin and dependencies of high-grade B-cell lymphomas with MYC and BCL2 rearrangements

10.1158/2643-3230.bcd-25-0099 · 2025 · External reference

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

10.1182/blood.2024024251 · 2024 · External reference

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

2023 · External reference

Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma

10.1200/jco.18.01583 · 2019 · External reference

Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy

10.1200/jco.18.01314 · 2019 · External reference

Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept

10.1038/s41375-025-02794-1 · 2025 · External reference

Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma

10.1038/s41408-024-01146-z · 2024 · External reference

Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma

10.1158/1078-0432.ccr-21-2949 · 2022 · External reference

Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries

10.18632/oncotarget.3479 · 2015 · External reference

DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma

10.1182/blood.2024025652 · 2025 · External reference

A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL

10.1182/bloodadvances.2020001949 · 2020 · External reference

Distinct molecular profile of IRF4-rearranged large B-cell lymphoma

10.1182/blood.2019002699 · 2020 · External reference

Reclassification of diffuse large B cell lymphoma to large B cell lymphoma with IRF4 rearrangement in an adult population

10.1111/his.14885 · 2023 · External reference

Large B-cell lymphoma with IRF4 gene rearrangements: differences in clinicopathologic, immunophenotypic and cytogenetic features between pediatric and adult patients

10.1016/j.humpath.2022.10.011 · 2023 · External reference

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma

10.1182/blood-2013-10-535443 · 2014 · External reference

Targetable genetic features of primary testicular and primary central nervous system lymphomas

10.1182/blood-2015-10-673236 · 2016 · External reference

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

10.1182/blood-2017-07-740993 · 2018 · External reference

Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis

10.1182/bloodadvances.2025017643 · 2026 · External reference

MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection

10.1111/his.12178 · 2013 · External reference

Programmed death ligand 1 (PD-L1) expression in lymphomas: state of the art

10.3390/ijms25126447 · 2024 · External reference

A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma

10.1172/jci164573 · 2025 · External reference

Anaplastic lymphoma kinase positive large B-cell lymphoma: diagnostic perils and pitfalls, an underrecognized entity

2021 · External reference

ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer

10.1126/sciadv.adg2263 · 2023 · External reference

Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma

10.1038/s41408-025-01323-8 · 2025 · External reference